A novel BRD4 degrader, ARV-825, attenuates lung fibrosis through senolysis and antifibrotic effect

Autor: Sato, Seidai, Koyama, Kazuya, Ogawa, Hirohisa, Murakami, Kojin, Imakura, Takeshi, Yamashita, Yuya, Kagawa, Kozo, Kawano, Hiroshi, Hara, Eiji, Nishioka, Yasuhiko
Zdroj: Respiratory Investigation; November 2023, Vol. 61 Issue: 6 p781-792, 12p
Abstrakt: Recent studies suggest that cellular senescence is related to the pathogenesis of idiopathic pulmonary fibrosis. However, cellular senescence has yet to be targeted therapeutically in clinical practice. ARV825, a recently developed BRD4 degrader, has been reported as a novel senolytic drug. Conversely, it has also been reported that BRD4 regulates the pro-fibrotic gene expression of fibroblasts. Therefore, this study focuses on the senolytic and anti-fibrotic effects of ARV825 and evaluated these effects on lung fibrosis.
Databáze: Supplemental Index